Galena Biopharma, Inc. (GALE)
(Real Time Quote from BATS)
$0.26 USD
-0.01 (-5.11%)
Updated Dec 29, 2017 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galena Biopharma, Inc. [GALE]
Reports for Purchase
Showing records 1 - 20 ( 132 total )
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
dropping coverage of Galena Biopharma, Inc. to focus our efforts elsewhere in the Biotechnology sector
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
GALE-301 Readout at ASCO Could Inform Future Development; Reit Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; PRESENT Interim Next Month and a Debt Financing
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Hoping for No News at PRESENT Interim; Target Tweaked to $5
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Product Divestiture Complete; Pipeline Focus Is Key
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
''401 ASH Data Continues EHA Momentum; Head-to-Head w/ IR Should Be Next
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
No More Looking Backwards with Big Step Forward
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Abstral Sold; Zuplenz Should Be Next; Now All Eyes on Clinical Program
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2015 Takeaways; CLDX - GALE New Data; TIL Progress Bodes Well for LBIO
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
ESMO Update - Optimal ''301 Dose Reduces Recurrences
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Galena Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.